Current Therapeutic Approaches to Cardio-Protection in Hypertension

  • David ParraEmail author
  • Augustus Hough
Hypertension and the Heart (SD Solomon and O Vardeny, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Hypertension and the Heart


Targeting a specific blood pressure based upon patient risk has been the approach to reducing cardiovascular risk in patients with hypertension. Drug selection was based upon compelling indications with titration and the addition of other agents as needed until the blood pressure target was achieved. However, new information has emerged describing improved methods for measuring blood pressure, a re-evaluation of blood pressure targets and additional therapeutic approaches that together may further reduce cardiovascular risk in patients with hypertension.


Ambulatory blood pressure monitoring Antihypertensive drugs Blood pressure Blood pressure determination Cardiovascular disease Chronotherapy Hypertension Hypertension resistant to conventional therapy Impedance cardiography Individualized medicine Masked hypertension White coat hypertension 


Compliance with Ethics Guidelines

Conflict of Interest David Parra and Augustus Hough declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307:1273–83.PubMedGoogle Scholar
  2. 2.
    Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Global status report on noncommunicable diseases 2010. Description of the global burden of NCDs, their risk factors and determinants Editors: World Health Organization. April 2011Chapter 1: Burden: mortality, morbidity and risk factors. Pages 9-31.Google Scholar
  4. 4.
    Go AS, Mozaffarian D, Roger VL, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.PubMedGoogle Scholar
  5. 5.
    Chow CK, Teo KK, Rangarajan S, for the PURE (Prospective Urban Rural Epidemiology) Study investigators, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959–68.PubMedGoogle Scholar
  6. 6.
    Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076–80.PubMedGoogle Scholar
  7. 7.••
    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16:14–26. Detailed guideline document addressing not only hypertension treatments and targets but also broader aspects of hypertension management including patient assessment and evaluation, non-pharmacologic interventions, and discussion on treatment-resistant hypertension.Google Scholar
  8. 8.
    Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension. 2010;55:195–200.PubMedGoogle Scholar
  9. 9.
    Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.PubMedGoogle Scholar
  10. 10.••
    O'Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. European Society of Hypertension Working Group on Blood Pressure Monitoring. J Hypertens. 2013;31:1731–68. An important review of clinical and practical information that allows a clinician to embark upon the provision of 24-hour ambulatory blood pressure monitoring.PubMedGoogle Scholar
  11. 11.
    National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical management of primary hypertension in adults. Clin Guidel 127.2011. Accessed January 26, 2014.
  12. 12.
    Hackam DG, Quinn RR, Ravani P, et al. for the Canadian Hypertension Education Program. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29:528–42.PubMedGoogle Scholar
  13. 13.
    Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.PubMedGoogle Scholar
  14. 14.
    Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29–38.PubMedGoogle Scholar
  15. 15.••
    Parati G, Stergiou GS, Asmar R, for the ESH Working Group on Blood Pressure Monitoring, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24:779–85. An excellent concise guideline that will prepare the clinician for incorporation of home blood pressure management in their practice.PubMedGoogle Scholar
  16. 16.
    Hermida RC, Smolensky MH, Ayala DE, Portaluppi F. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30:355–410.PubMedGoogle Scholar
  17. 17.
    Myers MG, Godwin M. Automated office blood pressure. Can J Cardiol. 2012;28:341–6.PubMedGoogle Scholar
  18. 18.
    Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.Google Scholar
  19. 19.
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88.PubMedGoogle Scholar
  20. 20.
    American Diabetes Association. Standards of medical care in diabetes 2014 (Position Statement). Diabetes Care. 2014;37:S14–80.Google Scholar
  21. 21.
    National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis. 2004;43:S1–290.Google Scholar
  22. 22.•
    Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114. Broadly supported consensus document detailing aspects relating to hypertension control in the elderly. Deals not only with therapeutic recommendations and considerations in the elderly but also issues related to pathophysiology and impact of hypertension in this high-risk group.PubMedGoogle Scholar
  23. 23.••
    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013;311:507–20. Recent guidelines with recommendations derived from clinical trial results instead of a mixture of physiological, observational, epidemiological and clinical trial results.Google Scholar
  24. 24.
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedGoogle Scholar
  25. 25.
    Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Weber MA, Bakris GL, Hester A, et al. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013;126:501–8.PubMedGoogle Scholar
  27. 27.
    Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.PubMedGoogle Scholar
  28. 28.
    Bangalor S, Qin J, Sloan S, Murphy SA, Cannon CP. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or atorvastatin evaluation and infection therapy-thrombosis in myocardial infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142–51.Google Scholar
  29. 29.
    Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the treating to new targets (TNT) trial. Eur Heart J. 2010;31:2897–908.PubMedGoogle Scholar
  30. 30.
    Cushman WC, Evans GW, Byington RP, et al. for the ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. Landmark trial questioning benefit of historically recommended more aggressive blood pressure lowering in patients with diabetes. Failed to show reduction in cardiovascular risk with intense blood pressure lowering. Adverse events were increased in the intense therapy arm.PubMedGoogle Scholar
  31. 31.
    Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD008277. DOI:  10.1002/14651858.CD008277.pub2.
  32. 32.
    Benavente OR, Coffey CS, Conwit R, for the SPS3 Study Group, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-15.Google Scholar
  33. 33.
    Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013. doi: 10.1136/bmj.f5689.
  34. 34.
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedGoogle Scholar
  35. 35.
    Denardo SJ, Gong Y, Nichols WM, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719–26.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Istituto Auxologico Italiano; European Society of Hypertension, Chinese Hypertension League. Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Jan 20]. Available from: NLM Identifier: NCT01563731.
  37. 37.
    Wake Forest Baptist Health; National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging. Systolic Blood Pressure Intervention Trial. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Jan 20]. Available from: NLM Identifier: NCT01206062.
  38. 38.
    Biomedis International Ltd.; Shimada K, RESPECT Study Group. Recurrent Stroke Prevention Clinical Outcome Study. In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Jan 20]. Available from: http:// NLM Identifier: NCT01198496.
  39. 39.•
    Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD006742. DOI:  10.1002/14651858.CD006742.pub2- This systemic review uses patient level randomized trial data to evaluate the benefit of pharmacologic treatment in patients with blood pressures of 140-160/90-99 mmHg and failed so show a clear benefit on cardiovascular outcome. Trial highlights need for further evaluations of expected treatment benefits in this large patient cohort prior.
  40. 40.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.Google Scholar
  41. 41.
    SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older per- sons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265:3255–64.Google Scholar
  42. 42.
    Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59:1110–7.PubMedGoogle Scholar
  43. 43.
    Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone Reduces Cardiovascular Events Compared With Hydrochlorothiazide: A Retrospective Cohort Analysis. Hypertension. 2011:689-94.PubMedGoogle Scholar
  44. 44.
    Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158:447–55.PubMedGoogle Scholar
  45. 45.
    Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Václavík J, Sedlák R, Plachý M, et al. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension. 2011;57:1069–75.PubMedGoogle Scholar
  47. 47.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.Google Scholar
  48. 48.
    Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.PubMedGoogle Scholar
  49. 49.
    Braunwald E, Domanski MJ, Fowler SE, for the The PEACE Trial Investigators, et al. Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery Disease. N Engl J Med. 2004;351:2058–68.PubMedGoogle Scholar
  50. 50.
    GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115 -1122.Google Scholar
  51. 51.
    Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) study investigators. N Engl J Med. 1995;332:80e5.Google Scholar
  52. 52.
    ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85.Google Scholar
  53. 53.
    Dahlöf B, Devereux RB, Kjeldsen SE, for the LIFE study group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedGoogle Scholar
  54. 54.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022e31.Google Scholar
  55. 55.
    Yusuf S, Teo K, Anderson C, for the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372:1174–83.Google Scholar
  56. 56.
    Yusuf S, Teo KK, Pogue J, of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) investigators, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.Google Scholar
  57. 57.
    Vijayaraghavan K, Deedwania P. Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. Cardiol Clin. 2011;29:137–56.PubMedGoogle Scholar
  58. 58.
    Parving HH, Brenner BM, McMurray JJV, for the ALTITUDE Investigators, et al. Cardiorenal Endpoints in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med. 2012;367:2204–13.Google Scholar
  59. 59.
    Fried LF, Emanuele N, Zhang JH, for the VA NEPHRON-D Investigators, et al. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. N Engl J Med. 2013;369:1892–903.PubMedGoogle Scholar
  60. 60.
    Shah S, Coakley C, Hough A, Parra D. Plasma Renin Activity Testing to Guide Triple Antirenin System Drug Therapy in a Patient With Difficult-to-Treat Hypertension. Ann Pharmacother. 2014;48:279–85.PubMedGoogle Scholar
  61. 61.•
    Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:1629–51. Demonstration of reduction in cardiovascular event endpoints with application of chronotherapy or bedtime dose of one antihypertensive versus morning administration of all agents. This simple intervention with endpoint benefit, underscores to need for further investigation into chronotherapy and evaluation of full day and night pattern of blood pressures versus solitary office based assessments.PubMedGoogle Scholar
  62. 62.
    Hermida RC, Ayala DE, Mojón A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34:1270–6.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD. J Am Soc Nephrol. 2011;22:2313–21.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Olson N, DeJough B, Hough A, Parra D. Plasma Renin Activity–Guided Strategy for the Management of Hypertension. Pharmacotherapy. 2012;32:446–55.PubMedGoogle Scholar
  65. 65.••
    Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hyperten. 2011;24:1164–80. Comprehensive review of rationale for, and integration of, plasma renin activity guided therapeutics into practice to help personalize hypertension therapy. Excellent review from pioneers of this strategy. Google Scholar
  66. 66.••
    Ferrario CM, Flack JM, Strobeck JE, Smits G, Peters C. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. Ther Adv Cardiovasc Dis. 2010;4:5–16. Detailed review of impedance cardiography testing and summary of data on its use in the management of hypertension. Novel technology with potential to drive individualization of hypertension therapy.PubMedGoogle Scholar
  67. 67.
    Schwartz GL, Bailey K, Chapman AB, Boerwinkle E, Turner ST. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013;26:957–64.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Krzesiński P, Gielerak G, Kowal J, Piotrowicz K. Usefulness of impedance cardiography in optimisation of antihypertensive treatment in patients with metabolic syndrome: a randomised prospective clinical trial. Kardiol Pol. 2012;70:599–607.PubMedGoogle Scholar
  69. 69.
    Krzesiński P, Gielerak G, Kowal J. A “patient-tailored” treatment of hypertension with use of impedance cardiography: A randomized, prospective and controlled trial. Med Sci Monit. 2013;19:242–50.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Turner ST, Boerwinkle E, O'Connell JR, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013;62:391–7.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Luo JQ, Wang LY, He FZ, et al. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics. 2014;15:201–8.PubMedGoogle Scholar
  72. 72.
    Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ. Sacks FM Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296–308.PubMedGoogle Scholar
  73. 73.
    Appel LJ, Giles TD, Black HR, Izzo Jr JL, Materson BJ, Oparil S, et al. ASH position paper: dietary approaches to lower blood pressure. J Am Soc Hypertens. 2010;4:79–89.PubMedGoogle Scholar
  74. 74.
    Taylor RA, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens. 2011;24:843–53.PubMedGoogle Scholar
  75. 75.
    Institute of Medicine. Sodium Intake in Populations: Assessment of Evidence. Washington, DC: National Academies Press. May 2013. Accessed January 30, 2014.
  76. 76.
    Mike Mitka MSJ. IOM Report: Evidence Fails to Support Guidelines for Dietary Salt Reduction. JAMA. 2013;309:2535–6.PubMedGoogle Scholar
  77. 77.
    Cogswell ME, Zhang Z, Carriquiry AL, Gunn JP, Kuklina EV, Saydah SH, et al. Moshfegh AJ Sodium and potassium intakes among US adults: NHANES 2003-2008. Am J Clin Nutr. 2012;96(3):647–57.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475–81.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Sealey JE, Parra D, Rosenstein R, Laragh JH. "Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension. 2010;55:e16. author reply e17.PubMedGoogle Scholar
  80. 80.
    Donazzan L, Mahfoud F, Linz D, Ewen S, Ukena C, Böhm M. Novel and nonpharmacologic approaches to cardio-protection in hypertension. Curr Hypertens Rep. 2014;16(5):430. doi: 10.1007/s11906-014-0430-3.
  81. 81.••
    Brook RD, Appel LJ, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension. 2013;61:1360–83. A comprehensive review of alternative approaches to lowering blood pressure with specific recommendations based on available evidence. Essential review for clinicians treating hypertension. PubMedGoogle Scholar
  82. 82.
    Blumenthal JA, Babyak MA, Hinderliter A, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170:126–35.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2014

Authors and Affiliations

  1. 1.Section of Clinical Pharmacy, Veterans Affairs Medical Center West Palm BeachWest Palm BeachUSA
  2. 2.Department of Experimental and Clinical PharmacologyUniversity of Minnesota College of PharmacyMinneapolisUSA

Personalised recommendations